Fatty acid amide hydrolase (FAAH) cleavable prodrugs of thyromimetics and combination with peripherally restricted FAAH inhibitors

A pharmaceutical composition comprising a fatty acid amide hydrolase (FAAH) cleavable prodrug of Formula (I′), or a pharmaceutically acceptable salt or solvate thereof:

• wherein:
• R1 and R2 are independently selected from hydrogen, —OR5, —NR5R6, C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, C3-C6heterocycloalkyl, phenyl, and —C1-C6alkyl-phenyl, wherein C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, C3-C6heterocycloalkyl, phenyl, and —C1-C6alkyl-phenyl are optionally substituted with one or more of halo, cyano, —OR5, —NR5R6, —S(O)2R5, or —S(O)2OR5;
• R3 and R4 are independently selected from —F, —Cl, —Br, and —I;
• R5 and R6 are independently selected from hydrogen and C1-C6alkyl;
• and
• R7 and R8 are independently selected from hydrogen, —F, —Cl, —Br, and —I;
• and a pharmaceutically acceptable excipient;
• further comprising a peripherally restricted FAAH inhibitor.